Scinopharm Taiwan Ltd. (1789)

Overview

ScinoPharm Taiwan, Ltd. operates as a key player in the pharmaceutical sector, focusing on research and development, production, and sales of active pharmaceutical ingredients (APIs). With its foundation laid in 1997 and headquartered in Tainan City, Taiwan, the company serves a broad spectrum of clients including major pharmaceutical entities across diverse regions such as Taiwan, Asia, Europe, India, the United States, and other international markets. ScinoPharm distinguishes itself by offering a vast range of products and specialized services catering to the dynamic needs of the pharmaceutical industry, including the development and manufacturing of both generic and novel pharmaceutical compounds. Through its comprehensive offerings and strategic alliances, like the one with Baxter International Inc. focusing on chemotherapy antiemetic drugs, ScinoPharm Taiwan, Ltd. reinforces its commitment to advancing pharmaceutical development and manufacturing on a global scale.

Products and Services

• Small Molecular Drugs

  These are conventional chemical compounds designed to interact with specific biological targets to achieve therapeutic effects. ScinoPharm specializes in the development and manufacturing of these drugs, leveraging advanced chemical synthesis techniques.

• Protein Drugs

  The company also delves into the realm of biologic drugs, focusing on protein-based therapeutics that offer novel treatment options for various diseases. These drugs are produced using complex biotechnological processes.

• Complex Natural Molecules and Derivatives

  ScinoPharm extends its expertise to the isolation and modification of natural molecules, which are often the basis for a wide range of pharmaceutical compounds, including complex derivatives with enhanced efficacy or safety profiles.

• Synthesis Services for Biochemistry Molecules

  This includes custom synthesis services for peptides and nucleic acids, catering to the needs for high-quality, research-grade biochemistry molecules for both academic and industry research purposes.

• Generic API Manufacturing Services

  Providing manufacturing services for generic active pharmaceutical ingredients, ScinoPharm supports the production of affordable medication options under strict quality control measures.

• Outsourcing Services

  The company offers a range of outsourcing services covering various aspects of drug research, development, and manufacturing. This allows clients to leverage ScinoPharm’s expertise and infrastructure for their specific needs.

• CRAM Services (Chemistry, Manufacturing, and Controls (CMC) Services)

  ScinoPharm provides comprehensive Contract Research and Manufacturing (CRAM) services, encompassing chemistry skill, analytical and regulatory support, chemical process development, clinical drug substance production, and consulting services for both the development and manufacturing phases of API and intermediates.

• Peptide Synthesis Technologies Development

  The company is at the forefront of developing advanced peptide synthesis technologies, which are pivotal in producing next-generation peptide therapeutics.

• Western Medicines and Other Chemical Materials

  Apart from APIs, ScinoPharm also develops and manufactures a variety of western medicines and essential chemical materials needed for the pharmaceutical and biotech industries.

• Albumin and Oligonucleotide Medicines

  These advanced therapeutic products represent the cutting edge of medical biotechnology, with ScinoPharm specializing in the development and production of albumin and oligonucleotide-based medications.

• Injections

  The company manufactures a range of injectable pharmaceuticals, ensuring high standards of safety, efficacy, and quality. These products cater to various therapeutic needs and application specifics.

• Biological Technology Services

  ScinoPharm offers a breadth of services in the biotechnological arena, including technical support and IP-related services, reinforcing its dedication to innovation and excellence in the bio-pharmaceutical sector.